Log in

Relevant bibliographies by topics / American Haibun / Journal articles

To see the other types of publications on this topic, follow the link: American Haibun.

Journal articles on the topic 'American Haibun'

Author: Grafiati

Published: 4 June 2021

Last updated: 30 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 44 journal articles for your research on the topic 'American Haibun.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Cole, Terry. "A Review of: “Franklyn S. Haiman, Religious Expression and the American Constitution”." Southern Communication Journal 71, no. 3 (2006): 309–11. http://dx.doi.org/10.1080/10417940600942851.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ghosh, Sweta, Rajbir Singh, Zachary M. Vanwinkle, et al. "Abstract 3250: Microbial metabolite, Urolithin A acts as chemo-sensitizing adjuvant in conventional drug therapies via modulation of drug transporters and EMT markers." Cancer Research 82, no. 12_Supplement (2022): 3250. http://dx.doi.org/10.1158/1538-7445.am2022-3250.

Full text

Abstract:

Abstract Colon cancer is the third leading cause in cancer related deaths in United States of America. Chemoresistance (drug resistance) of tumors is the primary reason for the failure of chemotherapy and a major cause of mortality in colon cancer. The molecular mechanisms involved in chemoresistance or methods to chemosensitization of cancer cells to chemotherapy remain elusive. Recent studies suggest that gut microbiota and microbial metabolites play a crucial role in the development and progression of colon cancer. Urolithin A (UroA) is a gut microbial metabolite derived from ellagitannin/e

APA, Harvard, Vancouver, ISO, and other styles

3

Azuaje-Alamo, Manuel. "“(In)comparable Poetries and Transpacific Networks of Translation”." Journal of World Literature 4, no. 4 (2019): 581–604. http://dx.doi.org/10.1163/24056480-00404007.

Full text

Abstract:

Abstract In 1957, writing in Spanish, the Mexican poet Octavio Paz (1914–1998) published the first complete translation into a Western language of the famous travel diary Oku no Hosomichi (The Narrow Road to the Deep North, 1702) by Matsuo Bashō (1644–1694). A thoroughly revised second edition followed in 1970, which included freer translations of Bashō’s haikus. In this definite edition, Paz attempted to synthesize the poetic effect of Bashō’s work for a Latin American readership. By using a textual and archival-based approach, this article analyses Paz’s two Spanish versions against the Japa

APA, Harvard, Vancouver, ISO, and other styles

4

Zhou, Haibin, Dimin Wu, Longchuan Bai, et al. "Abstract 4519: Discovery of highly potent, selective and efficacious STAT3 PROTAC degraders capable of achieving complete tumor regression." Cancer Research 84, no. 6_Supplement (2024): 4519. http://dx.doi.org/10.1158/1538-7445.am2024-4519.

Full text

Abstract:

Abstract STAT3 (signal transducer and activator of transcription 3) is a transcription factor and a promising therapeutic targets for cancer and other human diseases. We have previously reported the discovery of SD-36 and SD-91 as potent, selective and highly efficacious STAT3 degraders. In the present study, we report the discovery and extensive evaluation of highly potent, selective and efficacious new STAT3 degraders designed using novel cereblon ligands and novel STAT3 ligands. Our most potent STAT3 degraders are &gt;10-times more potent than SD-36 in inducing STAT3 degradation in cell

APA, Harvard, Vancouver, ISO, and other styles

5

Acharyya, Ranjan K., Longchuan Bai, Haibin Zhao, et al. "Abstract 4509: Discovery of potent and highly efficacious STAT3 PROTAC degraders capable of achieving long-lasting tumor regression." Cancer Research 84, no. 6_Supplement (2024): 4509. http://dx.doi.org/10.1158/1538-7445.am2024-4509.

Full text

Abstract:

Abstract STAT3 (signal transducer and activator of transcription 3) is a transcription factor and a promising therapeutic targets for cancer and other human diseases. We have previously reported the discovery of SD-36 and SD-91 as potent, selective and highly efficacious STAT3 degraders. In the present study, we report the discovery of highly potent, selective and efficacious new STAT3 degraders. These STAT3 degraders were designed using our high-affinity STAT3 ligands and high-affinity VHL-1 ligands, with UM-STAT3-3100 being the best. In direct comparison, UM-STAT3-3100 is &gt;10-times mo

APA, Harvard, Vancouver, ISO, and other styles

6

Zhao, Xiaobei, Jie Zhu, Yaqiong Zhou, et al. "Abstract 1886: BRY812, an anti-LIV-1 antibody drug conjugate with novel conjugation method for cancer therapeutics." Cancer Research 84, no. 6_Supplement (2024): 1886. http://dx.doi.org/10.1158/1538-7445.am2024-1886.

Full text

Abstract:

Abstract LIV-1, also known as SLC39A6 or ZIP6, belongs to the zinc transporter family and was initially identified as an estrogen-inducible gene in breast cancer. Immunohistochemical (IHC) analysis have revealed escalated LIV-1 expression in estrogen receptor-positive (ER+), hormone-treated tumors (both primary and metastatic sites) as well as ER-/PR-/Her2- (triple-negative) breast cancers. Notably, healthy human tissues exhibit limited LIV-1 expression, primarily in hormone regulated organs (prostate, uterus, and breast). The escalated expression of LIV-1 in breast and prostate cancer, as wel

APA, Harvard, Vancouver, ISO, and other styles

7

Zhou, Haibin, Dimin Wu, Longchuan Bai, et al. "Abstract 3881: Discovery of highly potent, selective and efficacious STAT3 PROTAC degraders capable of achieving long-lasting tumor regression." Cancer Research 84, no. 6_Supplement (2024): 3881. http://dx.doi.org/10.1158/1538-7445.am2024-3881.

Full text

Abstract:

Abstract STAT3 (signal transducer and activator of transcription 3) is a transcription factor and a promising therapeutic targets for cancer and other human diseases. We have previously reported the discovery of SD-36 and SD-91 as potent, selective and highly efficacious STAT3 degraders. In the present study, we report the discovery and extensive evaluation of new, highly potent, selective and efficacious new STAT3 degraders. In direct comparison, these compounds are &gt;50-times more potent than SD-36 in inducing STAT3 degradation in cells and demonstrates &gt;500-fold degradation sel

APA, Harvard, Vancouver, ISO, and other styles

8

Zhang, Xiaoting, Na Qin, Fenfen Ji, et al. "Abstract 4597: RNA m1A methyltransferase TRMT61A induces MAPK/ERK signaling and is a therapeutic target in colorectal cancer." Cancer Research 84, no. 6_Supplement (2024): 4597. http://dx.doi.org/10.1158/1538-7445.am2024-4597.

Full text

Abstract:

Abstract The widespread presence of N1-methyladenosine (m1A) modifications controls RNA metabolism and is pivotal to fundamental biological processes. However, the understanding of RNA m1A involved in cancer is still minimal. Here we reported the oncogenic role and the therapeutic targeting of RNA m1A methyltransferase TRMT61A in colorectal cancer (CRC). We observed consistent elevation of TRMT61A expression and RNA m1A levels in primary CRC tissues, which was significantly associated with poor patient survival in two independent cohorts (both P&lt;.001). CRISPR/Cas9 screenings revealed th

APA, Harvard, Vancouver, ISO, and other styles

9

Gaudio, Rudolf P. "John Haiman, Talk is cheap: Sarcasm, alienation, and the evolution of language. Oxford & New York: Oxford University Press, 1998. Pp. ix, 220. Hb $40.00, pb $18.95." Language in Society 29, no. 1 (2000): 117–20. http://dx.doi.org/10.1017/s0047404500211032.

Full text

Abstract:

In this “idiosyncratic personal essay,” Haiman applies his formidable erudition and powers of social observation to questions that North American linguists in general are, unfortunately, content to ignore: the evolutionary origins and historical development of metalanguage, i.e. the property of language that allows us to say “that which is not,” including something other than what we “really” mean. The interdisciplinary nature of this project – engaging evolutionary biology, anthropology, and psychology, in addition to virtually all the traditional subfields of formal/theoretical linguistics –

APA, Harvard, Vancouver, ISO, and other styles

10

Xiao, Haihua, Huangyu Jiang, Kunxian Feng, et al. "Abstract 5345: The application of CDK16 inhibitors in the treatment of triple-negative breast cancer." Cancer Research 83, no. 7_Supplement (2023): 5345. http://dx.doi.org/10.1158/1538-7445.am2023-5345.

Full text

Abstract:

Abstract Triple-negative breast cancer (TNBC) with estrogen receptor (ER), progesterone receptor (PR) and HER2 (c-erbB-2, neu) being negatively expressed in patient cancer tissues displayed its unique clinical pathological difference from other types of breast cancers. TNBC is more common in younger patients and more likely to have a family history of breast cancer. TNBCs more likely have poor prognosis and postsurgical recurrence, with strong invasiveness and metastasis. However, there is lack of effective and TNBC-targeting drugs. The non-typical CDK16 was found highly expressed in TNBCs and

APA, Harvard, Vancouver, ISO, and other styles

11

Zhang, Haiyun, and Xiaozhuo Chen. "Abstract 405: A new mechanism of drug resistance in cancer: extracellular ATP-induced resistance by macropinocytosis-mediated internalization and redox changes." Cancer Research 82, no. 12_Supplement (2022): 405. http://dx.doi.org/10.1158/1538-7445.am2022-405.

Full text

Abstract:

Abstract Drug resistance are responsible for most relapses and up to 90% of cancer related death. The opportunistic uptake of extracellular molecules has been named as a key emerging hallmark of cancer metabolism. In tumor microenvironment, intratumoral extracellular ATP (eATP) levels are 1,000 times or more higher than those in corresponding normal tissues. Our previous studies have shown that eATP can be taken up by cancer cell via macropinocytosis, leading to substantial increase in intracellular ATP levels. We found that this high intracellular ATP levels contribute to drug resistance in s

APA, Harvard, Vancouver, ISO, and other styles

12

Zhao, Xiaobei, Jie Zhu, zhenhua Wu, et al. "Abstract 1885: Developing a biparatopic anti-ROR1 antibody drug conjugate BR111 for hematological and solid tumor treatment." Cancer Research 84, no. 6_Supplement (2024): 1885. http://dx.doi.org/10.1158/1538-7445.am2024-1885.

Full text

Abstract:

Abstract ROR1 is a type I transmembrane protein that belongs to the ROR family. It is a receptor for Wnt family signaling molecules Wnt5a, and plays a critical role in various cellular processes, such as cell proliferation, survival, and migration. Being an oncofetal protein, ROR1 exhibits limited expression in most normal tissues. However, it is abnormally expressed in various hematological and solid cancers, contributing to the development and progression of many types of cancer. Due to its overexpression in cancer, ROR1 presents as a highly attractive target for antibody-drug conjugate (ADC

APA, Harvard, Vancouver, ISO, and other styles

13

Sun, Lichun, Mengli Yang, Haihua Xiao, et al. "Abstract 4957: The targeting drug conjugate Tye1001 displayed its potent anti-tumor efficacy in lymphoma." Cancer Research 83, no. 7_Supplement (2023): 4957. http://dx.doi.org/10.1158/1538-7445.am2023-4957.

Full text

Abstract:

Abstract Multiple drug-targeting strategies have been applied to drug development in order to reduce the toxic side effects of the traditional chemotherapy while enhancing its anti-tumor efficacy. Various peptides, proteins and antibodies are usually used to conjugate cytotoxic agents via acting as drug delivery vehicles. In our previous studies, we identified that peptides displayed their efficacious functions to deliver small molecules or oligo DNA to the target sites through ligand-receptor interactions and quick internalization. In our present study, we attempt to synthesize serial drug co

APA, Harvard, Vancouver, ISO, and other styles

14

Jia, Haiqun(John), Dorthy Fang, Molly Lobsinger, et al. "Abstract 2908: PT217, an anti-DLL3/anti-CD47 bispecific antibody, exhibits anti-tumor activity through novel mechanisms of action." Cancer Research 82, no. 12_Supplement (2022): 2908. http://dx.doi.org/10.1158/1538-7445.am2022-2908.

Full text

Abstract:

Abstract Small cell lung cancer (SCLC) is the most lethal subtype of lung cancers with few patients surviving more than 5 years from diagnosis. While SCLC initially responds well to standard chemotherapy treatment, chemotherapy-resistant recurrence is characteristic and available treatment options for recurrent and refractory diseases are limited. Immunotherapy as an alternative or additional treatment has been very successful in treating many cancers, yet it has shown disappointingly limited benefits in SCLC and notable treatment related toxicities have been observed. Delta like 3 (DLL3) is a

APA, Harvard, Vancouver, ISO, and other styles

15

Yang, Guiqun, Yanping Wang, Haijun Li, Mingming Chen, Yiwei Lin, and Xin Sun. "Abstract 1645: JAB-2485: A potent, highly selective small-molecule Aurora kinase A inhibitor that targets cell division." Cancer Research 83, no. 7_Supplement (2023): 1645. http://dx.doi.org/10.1158/1538-7445.am2023-1645.

Full text

Abstract:

Abstract Background: Aurora kinase A (AURKA), a crucial mitotic regulator, is frequently dysregulated in a wide range of cancers and contributes to clinical aggressiveness and poor patient survival. Abnormally activated AURKA promotes tumorigenesis through enhancing cancer cell proliferation, epithelial-mesenchymal transition, and cancer stem cell self-renewal, rendering it an attractive therapeutic target. We have developed JAB-2485, a highly selective small-molecule AURKA inhibitor. Methods: Biochemical and cell-based assays were performed to determine the IC50 of JAB-2485 on Aurora kinase f

APA, Harvard, Vancouver, ISO, and other styles

16

Bai, Longchuan, Haibin Zhou, Jiajia Zhou, et al. "Abstract 6057: Evaluation of a highly potent and selective STAT3 degrader as a new class of immunotherapy." Cancer Research 84, no. 6_Supplement (2024): 6057. http://dx.doi.org/10.1158/1538-7445.am2024-6057.

Full text

Abstract:

Abstract STAT3 (signal transducer and activator of transcription 3) is a transcription factor and a promising therapeutic target for cancer and other human diseases. In addition to its role in regulation of tumor cells, STAT3 also plays a key role in regulation of immunity and is a promising therapeutic target for the development of new immuno-oncology drugs. Our laboratory has previously reported the development of potent and highly selective STAT3 degraders, including SD-36 and SD-91. Extensive optimization of SD-36 and SD-91 yielded new, highly potent, selective and efficacious STAT3 degrad

APA, Harvard, Vancouver, ISO, and other styles

17

Guo, Jindong, Liwen Xiong, Haibin Yuan, Mengna Hu, Bei Zhang, and Ding Zhang. "Abstract 6121: Correlation of tumor immune microenvironment status and driver genes alterations in Chinese non-small-cell lung cancer patients." Cancer Research 82, no. 12_Supplement (2022): 6121. http://dx.doi.org/10.1158/1538-7445.am2022-6121.

Full text

Abstract:

Abstract Background: Patients with different driver genes show a variety of immunotherapy efficacy for non-small-cell lung cancer (NSCLC). In addition to PD-L1, the evaluation of the immune microenvironment contributes to a deeper understanding of the mechanisms of immunotherapy resistance. Methods: Tumor tissues from 2674 NSCLC patients were collected. Genetic alterations were profiled using targeted next-generation sequencing with 733 cancer-related genes panel. Immunohistochemistry was used to evaluate the PD-L1 tumor proportion score, (TPS) expression on the surface of tumor cells. Tumor-i

APA, Harvard, Vancouver, ISO, and other styles

18

Kang, Di, Yanping Wang, Xin Sun, et al. "Abstract 4535: JAB-26766: A small-molecule, orally bioavailable PARP7 inhibitor with high potency and selectivity." Cancer Research 84, no. 6_Supplement (2024): 4535. http://dx.doi.org/10.1158/1538-7445.am2024-4535.

Full text

Abstract:

Abstract Background: PARP7 (also referred to as TIPARP or ARTD14) is a mono-ADP-ribosyl transferase that inhibits type I interferon (IFN) signaling. Targeting PARP7 to restore antitumor immunity represents a promising treatment strategy. We have developed JAB-26766, an orally bioavailable, highly potent, and selective PARP7 inhibitor. Methods: A time-resolved fluorescence energy transfer (TR-FRET) assay was applied to determine the binding and inhibition of PARP7 by JAB-26766. IFN-β secretion assay, STAT1 phosphorylation assay, and ISG (interferon stimulated gene) mRNA assay were performed to

APA, Harvard, Vancouver, ISO, and other styles

19

Besnard, Jérémy, James Joseph, Haiyun Bai, et al. "Abstract 3930: AI-driven discovery and profiling of GTAEXS-617, a selective and highly potent inhibitor of CDK7." Cancer Research 82, no. 12_Supplement (2022): 3930. http://dx.doi.org/10.1158/1538-7445.am2022-3930.

Full text

Abstract:

Abstract Background: Uncontrolled cancer cell growth results from genetic lesions that disrupt mechanisms regulating cell cycle progression. Furthermore, these alterations invariably lead to dysregulated transcriptional programs that promote tumourigenesis and tumour growth. Cyclin-dependent kinase (CDK) 7 is an attractive therapeutic target in that it plays a dual role in regulating cell cycle progression and transcription. Knock-down studies and pharmacological inhibition of CDK7 have been shown to severely limit the proliferative capacity of cancer cells in vitro and in vivo. Methods: To ov

APA, Harvard, Vancouver, ISO, and other styles

20

Zhu, Jie, Xiaobei Zhao, Eileen Li, et al. "Abstract 3132: A novel dual drug antibody-drug conjugate targeting hTrop2 has synergetic anti-tumor activity in solid tumor models." Cancer Research 84, no. 6_Supplement (2024): 3132. http://dx.doi.org/10.1158/1538-7445.am2024-3132.

Full text

Abstract:

Abstract Antibody-drug conjugates (ADCs) are emerging therapeutic agents for targeted cancer treatment with remarkable clinical success. However, tumor heterogeneity and microenvironment complexity are still the major factors contributing to drug resistance, recurrence, and metastasis, which cannot be resolved with a mono therapy strategy. We’ve developed a novel dual drug ADC (BiADC), BR113, by conjugating an anti-hTrop2 antibody with a drug linker of a Topoisomerase I inhibitor payload, and another drug linker of an immune stimulator. Our studies show that the homogeneous ADC containing two

APA, Harvard, Vancouver, ISO, and other styles

21

Jia, Haiqun (John), Jack Li, Fen Pei, et al. "Abstract 4259: PT199, a next generation anti-CD73 mAb that inhibits both membrane-bound and soluble CD73 activity to completion without “hook effect”." Cancer Research 82, no. 12_Supplement (2022): 4259. http://dx.doi.org/10.1158/1538-7445.am2022-4259.

Full text

Abstract:

Abstract CD73, also known as ecto-5’-nucleotidase, is implicated in promoting immunosuppressive tumor microenvironment (TME) through production of adenosine. The first generation of anti-CD73 therapeutic antibodies currently in clinical studies have largely exhibited subdued clinical activities mainly due to several unfavorable characteristics such as incomplete enzyme inhibition and/or “hook effect”. These weaknesses are caused by the unfavorable target binding sites and enzyme inhibition mechanisms, which explains why these molecules do not inhibit soluble CD73 enzyme activity, or why the en

APA, Harvard, Vancouver, ISO, and other styles

22

Lafargue, Audrey M., Hailun Wang, Sivarajan T. Chettiar, et al. "Abstract 2968: TWIST1-induced suppression of oncogene-induced senescence in non-small cell lung cancer requires the transactivation domain of TWIST1." Cancer Research 84, no. 6_Supplement (2024): 2968. http://dx.doi.org/10.1158/1538-7445.am2024-2968.

Full text

Abstract:

Abstract Non-small cell lung carcinoma (NSCLC) is a major cause of cancer mortality. High expression of the epithelial-to-mesenchymal transition transcription factor TWIST1 is strongly associated with metastatic cancers and treatment resistance. Additionally, TWIST1 can upregulate O-GlcNAcylation which (1) is required to suppress fail-safe programs such as oncogene (KRasG12D)-induced senescence (OIS) to accelerate tumorigenesis in primary NSCLC tumors, and (2) is a potential modulator of DNA repair/radiation response. To decipher the domains and transcriptional targets required for tumorigenic

APA, Harvard, Vancouver, ISO, and other styles

23

Dai, Cheng, Juan Peng, Fei Yang, et al. "Abstract LB525: Discovery and characterization of ABSK111, a selective, CNS-penetrable, and broad-spectrum EGFR inhibitor targeting exon20 insertion, atypical and extracellular mutations." Cancer Research 82, no. 12_Supplement (2022): LB525. http://dx.doi.org/10.1158/1538-7445.am2022-lb525.

Full text

Abstract:

Abstract Epidermal growth factor receptor (EGFR) exon20 insertion mutations and atypical mutations account for about 9% and 20% of EGFR-mutated non-small cell lung cancer (NSCLC), respectively. Currently approved EGFR tyrosine kinase inhibitors (TKIs) have shown efficacy in NSCLC patients with exon20 insertion and atypical mutations, but with limited overall response and high rate of EGFR-related severe adverse events. This may be associated with the inhibition of wild-type (WT) EGFR. ABSK111 is a highly potent, selective, and CNS-penetrable EGFR inhibitor, targeting multiple EGFR and HER2 mut

APA, Harvard, Vancouver, ISO, and other styles

24

Liu, Yarong, Jingwei Sun, Yao Sheng, et al. "Abstract 4062: The discovery and development of a CRISPR/Cas9-engineered tumor-infiltrating lymphocytes product (GT316) as a next-generation TIL therapy." Cancer Research 83, no. 7_Supplement (2023): 4062. http://dx.doi.org/10.1158/1538-7445.am2023-4062.

Full text

Abstract:

Abstract Adoptive cell therapy by tumor-infiltrating lymphocytes (TILs) has demonstrated promising therapeutic effects in multiple types of solid tumors and significantly prolonged the survival of late-stage patients. However, the “prone-to-exhaustion” phenotype of the final TIL product after rapid expansion during manufacture and the presence of various immunosuppressive mechanisms in tumor microenvironment (TME) compromises the persistence and anti-tumor efficacy of TIL post infusion. To discover potential immunoregulatory targets that could maximize the function of TIL, we established a gen

APA, Harvard, Vancouver, ISO, and other styles

25

Ying, Haiyan, Wenqun Xin, Haibing Deng, et al. "Abstract LB317: Discovery and characterization of a next-generation FGFR inhibitor overcoming FGFR resistant mutations." Cancer Research 83, no. 8_Supplement (2023): LB317. http://dx.doi.org/10.1158/1538-7445.am2023-lb317.

Full text

Abstract:

Abstract Introduction: FGFRs play important roles in cancer development and inhibition of FGFR could disrupt tumor cell proliferation and growth. Four selective FGFR inhibitors have been approved (erdafitinib, pemigatinib, infigratinib, and futibatinib) and several others are in clinical development. Unfortunately upon treatment with these first-generation FGFR inhibitors, acquired resistance often develops and is frequently associated with the emergence of secondary FGFR2/3 kinase domain mutations. Therefore, selectively targeting FGFR2/3 as well as their resistant mutations may render a seco

APA, Harvard, Vancouver, ISO, and other styles

26

Li, Jack, Haiqun Jia, Erin Ramsey, et al. "Abstract 4260: PT886, an anti-claudin18.2/anti-CD47 bispecific antibody constructed with the PACbody࣪ and SPECpair࣪ technology platforms, exhibits robust anti-tumor activity in a pancreatic cancer xenograft model." Cancer Research 82, no. 12_Supplement (2022): 4260. http://dx.doi.org/10.1158/1538-7445.am2022-4260.

Full text

Abstract:

Abstract Claudin 18.2 (CLDN18.2) is a surface protein overexpressed in gastric and pancreatic tumors and has been demonstrated to be a clinically validated target for developing mAb and CAR-T therapies for these tumors. CD47 is a well-established “don’t eat me” signal and commonly overexpressed by many types of tumor cells as a mechanism for evading the innate immune system. It has been demonstrated in clinic that blocking CD47 from interacting with its ligand SIRPα leads to reduced growth of certain hematological tumors, presumably by activating the innate immune system against tumor cells. H

APA, Harvard, Vancouver, ISO, and other styles

27

Borrego, Santiago G., Cristina Cirauqui, David Gómez-Sánchez, et al. "Abstract 4489: N-Cadherin acts as a predictive biomarker for anti-FGFR therapy in KRAS wild-type NSCLC." Cancer Research 83, no. 7_Supplement (2023): 4489. http://dx.doi.org/10.1158/1538-7445.am2023-4489.

Full text

Abstract:

Abstract Background: Lung cancer is the leading cause of cancer-related deaths worldwide. FGFR1 has been associated with tumorigenesis in a variety of tumor types, including lung cancer. As a therapeutic approach, their inhibition has been attempted and was initially focused on FGFR1-amplified tumors, though with limited success. Preliminary data of our group suggests that N-Cadherin play a key role for the oncogenicity of FGFR1 and predict FGFR-targeted therapy efficacy in Non-small cell lung cancer (NSCLC). However, it is possible that other biomarkers, together with N-Cadherin, can determin

APA, Harvard, Vancouver, ISO, and other styles

28

Khan, Muhammad Ajmal, Jinhee Chang, Triet Nguyen, et al. "Abstract 1444: Modeling Twist1 overexpression in a pancreatic ductal adenocarcinoma mouse model." Cancer Research 84, no. 6_Supplement (2024): 1444. http://dx.doi.org/10.1158/1538-7445.am2024-1444.

Full text

Abstract:

Abstract Pancreatic ductal adenocarcinoma (PDAC) is an extremely lethal cancer characterized by very poor survival outcomes. Genomic sequencing of human PDAC tissues and cell lines have identified four molecular subtypes: quasimesenchymal (QM), pancreatic progenitor, immunogenic, and aberrantly differentiated endocrine exocrine (ADEX). QM-PDAC has the worse prognosis, but no in vivo models exist for this molecular subtype. Our preliminary analysis using publicly available data demonstrated that the epithelial-to-mesenchymal transition (EMT) transcription factor TWIST1 is upregulated in QM-PDAC

APA, Harvard, Vancouver, ISO, and other styles

29

Xu, Yan, Junqing Liang, Shuwen Jiang, et al. "Abstract 1890: HMA800067, a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior anti-tumor activity to daratumumab in preclinical B-cell malignancies models." Cancer Research 84, no. 6_Supplement (2024): 1890. http://dx.doi.org/10.1158/1538-7445.am2024-1890.

Full text

Abstract:

Abstract Introduction: Daratumumab (Dara), an anti-CD38 monoclonal antibody, has been widely used in the treatment of multiple myeloma (MM). However, some of MM patients exhibit primary or acquired resistance to Dara therapy. A CD38 targeting antibody-drug conjugate (ADC) HMA800067 is developed, in which Dara was conjugated with cytotoxic payload via a novel linker, aiming to have superior anti-tumor efficacy to Dara, even in the subjects with resistance to Dara treatment. Methods: HMA800067 was characterized by ELISA-based binding assay, cell internalization assay, antibody-dependent cell-med

APA, Harvard, Vancouver, ISO, and other styles

30

Zhou, Haikun, Tao Han, Lei Tuo, et al. "Abstract 6400: Tislelizumab combined with XELOX as a neoadjuvant therapy for locally advanced gastric and gastroesophageal junction adenocarcinomas: A prospective, phase II trial." Cancer Research 84, no. 6_Supplement (2024): 6400. http://dx.doi.org/10.1158/1538-7445.am2024-6400.

Full text

Abstract:

Abstract Background: Combing anti-PD-(L)1 antibody with chemotherapy in neoadjuvant therapy of gastric/gastroesophageal junction (G/GEJ) adenocarcinomas is a promising strategy, but clinical data are remain insufficient. Whether immunotherapy biomarkers in previous studies (TMB, MSI, PD-L1, etc.) have equivalent predictive value for G/GEJ remains to be verified. In this phase II clinical trial of tislelizumab in combination with chemotherapy, potential therapy-related biomarkers in tumor samples, and changes in the tumor microenvironment during treatment were analyzed, and a predictive model f

APA, Harvard, Vancouver, ISO, and other styles

31

Mishra, D., G. Naidu, V. Kumar, et al. "OP0108 RANDOMIZED CONTROLLED TRIAL OF ORAL CORTICOSTEROIDS IN AXIAL SPONDYLOARTHROPATHY: MODIFIED COBRA REGIME." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 70.2–71. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4746.

Full text

Abstract:

Background:There is an unmet need of anti-inflammatory agents in AxSpA after NSAID failure. This is especially true for patients with persisting high disease activity and not having access to anti-TNFα. In this regard, corticosteroids may be helpful as a short-term measure. However, current guidelines recommend against oral corticosteroids citing insufficient evidence of efficacy.1. Also, there is an assumption that the dose required for benefit is much higher than RA, and thus untenable. It is unclear whether starting with a high dose followed by rapid taper would be effective (like the COBRA

APA, Harvard, Vancouver, ISO, and other styles

32

Yu, Raymond, Yong Tong, Huarui Lu, et al. "Abstract 3432: A novel anti-CLDN6-CD137 bispecific antibody (NBL-028) for treating Claudin 6 positive solid tumors." Cancer Research 82, no. 12_Supplement (2022): 3432. http://dx.doi.org/10.1158/1538-7445.am2022-3432.

Full text

Abstract:

Abstract Claudin-6 is a tetraspan membrane protein associated with tight junction formation. Its expression in normal tissues is restricted to the fetal organs but is not detected in the adult tissues. Increased expression of CLDN6 has been shown in several human malignancies such as testicular, ovarian, uterine, liver and lung adenocarcinoma, and is associated with poor prognosis in these cancer patients. Therefore, CLDN6 is a promising tumor-associated antigen (TAA) for tumor-targeting therapeutics such as CART and T cell engaging bispecific antibodies. CD137 co-stimulation has been reported

APA, Harvard, Vancouver, ISO, and other styles

33

Stejskal, Pavel, Josef Srovnal, Emil Berta, et al. "Abstract 1956: Perioperative opioid analgesia affects the circulating tumor cells levels in colorectal cancer patients." Cancer Research 82, no. 12_Supplement (2022): 1956. http://dx.doi.org/10.1158/1538-7445.am2022-1956.

Full text

Abstract:

Abstract Purpose Colorectal cancer (CRC) is one of the most common cancers worldwide and metastases-related death is the main cause of its high mortality. Previous studies showed the poorer survival in colorectal cancer patients treated perioperatively with morphine in comparison to piritramide. Circulating tumor cells (CTCs) are considered as precursors of distant metastatic spread and can act as an independent prognostic and predictive biomarker. The hypothesis that different pain-killers used in perioperative period can affect the CTCs levels was tested. Patients and methods In total, 100 C

APA, Harvard, Vancouver, ISO, and other styles

34

Aceituno, Veronica Castro, Tiantian Cui, Haihua Feng, Linlin Yang, Sindhu Nair, and Terence M. Williams. "Abstract 7080: Regulation of caveolin-1 by RAS/RAF oncogenic signaling in cancer cells." Cancer Research 84, no. 6_Supplement (2024): 7080. http://dx.doi.org/10.1158/1538-7445.am2024-7080.

Full text

Abstract:

Abstract Background and Purpose: Caveolin-1 (Cav-1), a scaffolding protein implicated in cellular signaling and membrane dynamics, undergoes intricate regulation at multiple levels. Recent evidence has suggested a potential association between oncogenic mutations and alterations in Cav-1 expression. Our study aimed to comprehensively explore how RAS/RAF mutations influence Cav-1 expression in cancer cells, as well as the underlying molecular mechanisms, using tetracycline (tet)-inducible cell lines and cancer cell lines harboring endogenous BRAF or KRAS mutations. Experimental Design: We asses

APA, Harvard, Vancouver, ISO, and other styles

35

Stejskal, Pavel, Josef Srovnal, Emil Berta, et al. "Abstract 5589: The effect of morphine-based perioperative analgesia on circulating tumor cells dissemination in colorectal cancer patients." Cancer Research 83, no. 7_Supplement (2023): 5589. http://dx.doi.org/10.1158/1538-7445.am2023-5589.

Full text

Abstract:

Abstract Purpose: Circulating tumor cells (CTCs) are primary or metastatic tumor cells shed into the bloodstream and are considered precursors of distant metastatic spread and can act as an independent prognostic and predictive biomarker. Colorectal cancer (CRC) is the leading cause of cancer-related deaths worldwide and metastasis is the major cause of death. Previous studies showed poorer survival in CRC patients treated perioperatively with morphine in comparison to piritramide. Patients and Methods: In total, 150 CRC stage I-III patients undergoing either radical or laparoscopic surgery we

APA, Harvard, Vancouver, ISO, and other styles

36

Ying, Haiyan, Nannan Zhang, Haibing Deng, et al. "Abstract LB328: Discovery & characterization of a next-generation FGFR4 inhibitor overcoming resistant mutations." Cancer Research 83, no. 8_Supplement (2023): LB328. http://dx.doi.org/10.1158/1538-7445.am2023-lb328.

Full text

Abstract:

Abstract Introduction: Aberrant activation of FGF19-FGFR4 signaling pathway plays an essential role in the tumorigenesis of Hepatocellular carcinoma (HCC) and FGFR4 inhibitors have shown preliminary efficacy in recent clinical trials for patients with FGF19 overexpression. However, the observed responses only lasted a few months before tumors relapse. Acquired FGFR4 resistant mutations were found in ~30% of FGFR4 inhibitor responsive patients. Similar FGFR4 mutations haven also been found de novo in about 7-10% of Rhabdomyosarcoma (RMS) and ER-treated invasive lobular carcinoma patients. First

APA, Harvard, Vancouver, ISO, and other styles

37

Corrales-Guerrero, Sergio, Tiantian Cui, Veronica Castro-Aceituno, et al. "Abstract 2407: Targeting ribonucleotide reductase subunit 2 (RRM2) to radio-sensitize glioblastoma." Cancer Research 83, no. 7_Supplement (2023): 2407. http://dx.doi.org/10.1158/1538-7445.am2023-2407.

Full text

Abstract:

Abstract Purpose: Despite aggressive multimodality treatments, the median survival of glioblastoma (GBM) remains within the range of 12-15 months after diagnosis with standard-of-care surgery, radiation therapy (RT) and temozolomide (TMZ). Resistance frequently arises, exacerbating the clinical difficulty of treating GBM. Therefore, new or enhanced therapeutic strategies are critically needed. Radiation treatment induces DNA damage that cells must repair for their survival, and DNA repair requires a constant and balanced supply of dNTPs. The ribonucleotide reductase (RNR) catalyzes the rate-li

APA, Harvard, Vancouver, ISO, and other styles

38

Castagna, Antonella, David Shu Cheong Hui, Kathleen M. Mullane, et al. "548. Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with moderate COVID-19." Open Forum Infectious Diseases 7, Supplement_1 (2020): S340. http://dx.doi.org/10.1093/ofid/ofaa439.742.

Full text

Abstract:

Abstract Background Remdesivir (RDV) has been shown to shorten recovery time and was well tolerated in patients with severe COVID-19. Here we report baseline characteristics associated with clinical improvement at day (d) 14. Methods We enrolled hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation &gt;94% on room air, and radiological evidence of pneumonia. Patients were randomized 1:1:1 to receive 5d or 10d of intravenous RDV once daily plus standard of care (SoC), or SoC only. For this analysis, patients were followed through discharge, d14, or death. Baseline dem

APA, Harvard, Vancouver, ISO, and other styles

39

Haibel, H., J. L. Vahldiek, S. Angermair, et al. "POS1209 SUCCESSFUL TREATMENT OF SEVERE COVID-19 PNEUMONIA AND CYTOKINE RELEASE WITH SIMULTANEOUS TOCILIZUMAB AND ANAKINRA WITH ONE-MONTH FOLLOW-UP." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 887.2–888. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2289.

Full text

Abstract:

Background:Severe and life threating COVID-19 pneumonia is often characterized by local and systemic immune-mediated hyperinflammation At the early disease stage activated monocytes are migrating to the lung and cause the typical opac infiltrates, which lead to an reduction of oxygen uptake. These pathophysiological observations and the fact that corticosteroids are so far the only drug, which has shown significant improvement, was the rationale use this combination anti-inflammatory drugs in severe Covid-19 disease. Interleukin (IL)-6 and IL-1 blockade alone, respectively showed contradictory

APA, Harvard, Vancouver, ISO, and other styles

40

"THE AMERICAN SOCIETY OF HEMATOLOGY." Blood 114, no. 22 (2009): R23. http://dx.doi.org/10.1182/blood.v114.22.r23.r23.

Full text

Abstract:

Abstract The Society gratefully acknowledges the time and effort of the following individuals who served as reviewers of abstracts for this meeting: ASH ABSTRACTS COORDINATING REVIEWERS Blanche P. Alter Stephen M. Ansell Ralph B. Arlinghaus Scott Armstrong Asad Bashey Philip Bierman Neil Blumberg Chiara Bonini Dominique Bonnet Jacqueline Boultwood Rena Buckstein John C. Byrd Marc Carrier Lucio H. Castilla Selina Chen-Kiang Nicholas Chiorazzi Jorge Cortes-Franco Claire E. Dearden Mary C. Dinauer Harry Paul Erba Carolyn A. Felix Pierre Fenaux Debra L. Friedman Irene M. Ghobrial Jason R. Gotlib B

APA, Harvard, Vancouver, ISO, and other styles

41

Murakami, Christopher. "Itadakimasu, ikigai, and wabi-sabi: Poems and reflections on trust after the U.S. Agroecology Summit 2023." Journal of Agriculture, Food Systems, and Community Development, April 16, 2024, 1–5. http://dx.doi.org/10.5304/jafscd.2024.133.003.

Full text

Abstract:

First paragraphs: “How can I trust you?” Agroecology how? A murmuration Itadakimasu The third panel of the U.S. Agroecology Summit 2023 centered scholars, activists and advocates who, from a variety of institutional positions, have built trusting relationships with farmers and social movements. During the Q and A session, I asked the panel how, in that moment, we might be able to continue to build trust to support relationship-building in the movement for agroecology in North America. The panelists deferred to the audience, and Jonny Bearcub Stiffarm, surrounded by several of her Indigenous

APA, Harvard, Vancouver, ISO, and other styles

42

Thanh Huyen, Le, Dao Sy Duc, Nguyen Xuan Hoan, Nguyen Huu Tho, and Nguyen Xuan Viet. "Synthesis of Fe3O4-Reduced Graphene Oxide Modified Tissue-Paper and Application in the Treatment of Methylene Blue." VNU Journal of Science: Natural Sciences and Technology 35, no. 3 (2019). http://dx.doi.org/10.25073/2588-1140/vnunst.4883.

Full text

Abstract:

Graphene-based composites have received a great deal of attention in recent year because the presence of graphene can enhance the conductivity, strength of bulk materials and help create composites with superior qualities. Moreover, the incorporation of metal oxide nanoparticles such as Fe3O4 can improve the catalytic efficiency of composite material. In this work, we have synthesized a composite material with the combination of reduced graphene oxide (rGO), and Fe3O4 modified tissue-paper (mGO-PP) via a simple hydrothermal method, which improved the removal efficiency of the of methylene blue

APA, Harvard, Vancouver, ISO, and other styles

43

Thi Phuong Thao, Nguyen, Nguyen Thi Thi, and Nguyen Thi Hong Hanh. "Hypolipidemic effect of ethanol extract from Mesona chinensis Benth. in high fat diet-induced obesity mice." VNU Journal of Science: Medical and Pharmaceutical Sciences 35, no. 1 (2019). http://dx.doi.org/10.25073/2588-1132/vnumps.4160.

Full text

Abstract:

Mesona chiensis Benth. is a natural and safe pharmaceutical ingredient with many nutrients and special medical functions. The aim of this study was to investigate the prevention and treatment effect of ethanol extract from Mesona chiensis Benth. on the plasma lipid concentration of high fat diet-induced obesity mice. Male white mice (Mus musculus) 5 - 6 weeks of age were fed a high-fat diet including standard pellets (65% in weight) and boiled lard (35% in weight) for 6 weeks model obese mice. The study was divided into 2 periods: the prevention period for 4 weeks and the treatment period for

APA, Harvard, Vancouver, ISO, and other styles

44

Witney, Cynthia, Lelia Green, Leesa Costello, and Vanessa Bradshaw. "Creativity in an Online Community as a Response to the Chaos of a Breast Cancer Diagnosis." M/C Journal 16, no. 1 (2013). http://dx.doi.org/10.5204/mcj.598.

Full text

Abstract:

IntroductionA catastrophe is often considered to be a final decisive event, resulting in a disastrous end. Two recent examples of catastrophes satisfying this definition were the 2012 super storm Sandy in the United States of America and the 2011 floods in Brisbane, Australia. The progress of these disasters was reported worldwide, yet coverage soon disappeared from the headlines, leaving people to deal with the aftermath of rebuilding homes, businesses and lives. The diagnosis of breast cancer is an individual’s catastrophic event. While not on the community-wide scale of the disasters mentio

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!